Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.43 |
| ▸ | BAD | Q92934 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5778255 | 0.84 | PTGS2 (0.40) | PTGS2BADMAOBAOC3PTGS1 | |
| SCHEMBL28748021 | 0.81 | PTGS2 (0.39) | PTGS2BADMAOBAOC3PTGS1 | |
| SCHEMBL5780574 | 0.76 | AOC3 (0.38) | PTGS2BADMAOBAOC3PTGS1 | |
| Bromide SCHEMBL5783254 | 0.75 | PTGS2 (0.37) | PTGS2BADMAOBPTGS1EPHB4 | |
| SCHEMBL6027214 | 0.74 | PRKACA (0.41) | BADMAOBAOC3 | |
| SCHEMBL29707155 | 0.73 | AOC3 (0.42) | PTGS2BADAOC3 | |
| SCHEMBL232439 | 0.72 | AOC3 (0.49) | BADAOC3 | |
| SCHEMBL25165979 | 0.70 | AOC3 (0.44) | BADMAOBAOC3 | |
| SCHEMBL6184460 | 0.70 | MTNR1A (0.38) | PTGS2MAOBAOC3MAPTMEN1 | |
| SCHEMBL10430644 | 0.70 | POLB (0.48) | BADAOC3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254904-B1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | EISAI CO LTD (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-6784192-B2 | NA+ CHANNEL INHIBITORY ACTION IS USEFUL FOR THERAPY AND PREVENTION FOR EXAMPLE, ARRHYTHMIA, VARIOUS NEURALGIAS AND ANALGESIC | EISAI CO., LTD. (JP) | 2004-08-31 | — | — | US | disclosed |
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-11-27 | — | — | US | disclosed |
| CN-1395575-A | Novel piperidine compounds and drugs containing the same | EISAI CO LTD (JP) | 2003-02-05 | — | — | CN | disclosed |
| EP-1254904-A1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | TRPV1, CACNA1D, KCND2 | PTGS2 1830/4885BAD 1179/4885MAOB 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.